Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Nursing, Stockholm, Sweden.
Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Nursing, Stockholm, Sweden.
Breast. 2020 Jun;51:85-93. doi: 10.1016/j.breast.2020.03.004. Epub 2020 Mar 20.
Neoadjuvant chemotherapy causes distressing symptoms, which have to be managed by patients at home. Assessing and acting upon relevant patient-reported symptoms regularly with the support of mHealth such as apps, has shown to decrease symptom burden and improve health-related quality of life (HRQoL). There is a lack of apps for patients with breast cancer which are tested in rigorous trials and only a few include interactive components for immediate clinical management. The aim of this study was to evaluate whether the use of the interactive app Interaktor improves patients' levels of symptom burden and HRQoL during neoadjuvant chemotherapy for breast cancer.
This randomized controlled trial included patients in an intervention group (n = 74) and a control group (n = 75), recruited at two university hospitals in Stockholm, Sweden. The intervention group used Interaktor for symptom reporting, self-care advice and support from health-care professionals during treatment, and the control group received standard care alone. Self-reported symptoms and HRQoL were assessed at two time points to determine differences between the groups.
The intervention group rated statistically significant less symptom prevalence in nausea, vomiting, feeling sad, appetite loss and constipation. Overall symptom distress and physical symptom distress were rated statistically significant lower in the intervention group. Further, emotional functioning was rated statistically significant higher in the intervention group.
By using the Interaktor app in clinical practice, patients get individual support when managing treatment-related symptoms during neoadjuvant chemotherapy for breast cancer, leading to decreased symptom burden and improved emotional functioning.
新辅助化疗会引起令人痛苦的症状，这些症状需要患者在家中自行处理。通过使用移动健康（如应用程序）定期评估和处理相关的患者报告症状，并支持患者，已经证明可以减轻症状负担并改善健康相关生活质量（HRQoL）。目前缺乏经过严格试验测试的适用于乳腺癌患者的应用程序，并且只有少数应用程序包含用于即时临床管理的交互组件。本研究旨在评估交互式应用程序 Interaktor 是否可以改善接受新辅助化疗的乳腺癌患者的症状负担和 HRQoL 水平。
这是一项随机对照试验，纳入了瑞典斯德哥尔摩两家大学医院的干预组（n=74）和对照组（n=75）的患者。干预组在治疗期间使用 Interaktor 报告症状、自我护理建议和获得医疗保健专业人员的支持，而对照组仅接受标准护理。在两个时间点评估自我报告的症状和 HRQoL，以确定两组之间的差异。
干预组在恶心、呕吐、感到悲伤、食欲减退和便秘方面的症状发生率明显较低。干预组的总体症状困扰和身体症状困扰也明显较低。此外，干预组的情绪功能评分明显较高。
通过在临床实践中使用 Interaktor 应用程序，患者在接受新辅助化疗期间管理与治疗相关的症状时会得到个性化的支持，从而减轻症状负担并改善情绪功能。
